XML 75 R60.htm IDEA: XBRL DOCUMENT
v3.24.3

Commitments and Contingencies (Details) - USD ($) $ in Thousands |  | 1 Months Ended | 9 Months Ended
--- | --- | --- | ---
Jul. 14, 2023 | Jun. 30, 2023 | Sep. 30, 2024
Non-cancelable commitments for product manufacturing and supply costs |  |  | $ 14,700
Pharmosa License Agreement |  |  |
Upfront license fee to be paid |  | $ 10,000 |
Accrued additional upfront license fee |  | 3,500 |
Maximum potential development milestone payments |  | 37,750 |
Milestone payments Pharmosa is to receive per terms of the license agreement |  | 10,000 |
Pharmosa License Agreement | North America |  |  |
Maximum potential sales milestones |  | 185,000 |
Pharmosa License Agreement | Other then North America |  |  |
Maximum potential sales milestones |  | $ 150,000 |
Chasm Technologies |  |  |
Maximum Net Sales Threshold As Basis For Payment Of Future Contingent Royalties |  |  | 1,500
Net sales earned relating to payment of future contingent royalties |  |  | 200
Agreement With LGM Pharma, LLC |  |  |
Purchase Commitment, Remaining Minimum Amount Committed |  |  | $ 2,700
Expiration term of agreement |  |  | 5 years
Amended and Restated Commercial Manufacturing Services and Supply Agreement with Lonza Tampa LLC |  |  |
Initial term | 5 years |  |
Termination term for FDA rejection | 60 days |  |
Termination term for FDA delay | 120 days |  |
Percentage of reimburse | 50.00% |  |
Aggregate exceed | $ 2,500 |  |
Term of submission | 24 months |  |
Initial term | 12 months |  |

X
- Definition Amount of accrued additional upfront license fee. + References No definition available. + Details
Name: | lqda_AccruedAdditionalUpfrontLicenseFee
Namespace Prefix: | lqda_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Expiration term of the agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | lqda_AgreementExpirationTerm
Namespace Prefix: | lqda_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Initial term of commercial manufacturing services and supply agreement. + References No definition available. + Details
Name: | lqda_CommercialManufacturingServicesAndSupplyAgreementInitialTerm
Namespace Prefix: | lqda_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Term term upon written notice in the event of application for regulatory approval is not received by FDA within the specified period. + References No definition available. + Details
Name: | lqda_CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaDelay
Namespace Prefix: | lqda_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Term term upon written notice in the event of application for regulatory approval is rejected by the FDA. + References No definition available. + Details
Name: | lqda_CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaRejection
Namespace Prefix: | lqda_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Initial term of submission of quarterly forecast of expected production considered as binding firm order. + References No definition available. + Details
Name: | lqda_InitialTermOfSubmissionOfQuarterlyForecastOfExpectedProductionBindingFirmOrder
Namespace Prefix: | lqda_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The maximum net sales amount that is used as the basis in determining the payment of future contingent royalties. + References No definition available. + Details
Name: | lqda_MaximumNetSalesThresholdAsBasisForPaymentOfFutureContingentRoyalties
Namespace Prefix: | lqda_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The maximum potential development milestone payments per the agreement. + References No definition available. + Details
Name: | lqda_MaximumPotentialDevelopmentMilestonePayments
Namespace Prefix: | lqda_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The maximum potential sales milestones to be paid. + References No definition available. + Details
Name: | lqda_MaximumPotentialSalesMilestones
Namespace Prefix: | lqda_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of milestone payments payable. + References No definition available. + Details
Name: | lqda_MilestonePaymentsPayable
Namespace Prefix: | lqda_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of net sales earned by the entity relating to payment of future contingent royalties. + References No definition available. + Details
Name: | lqda_NetSalesEarnedRelatingToPaymentOfFutureContingentRoyalties
Namespace Prefix: | lqda_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of non-cancelable future commitments for product manufacturing and supply costs. + References No definition available. + Details
Name: | lqda_NonCancelableFutureCommitmentForProductManufacturingAndSupplyCosts
Namespace Prefix: | lqda_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of cash outflow for upfront license fee. + References No definition available. + Details
Name: | lqda_PaymentForUpfrontLicenseFee
Namespace Prefix: | lqda_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of reimbursement of documented out of pocket expenditures for any capital equipment. + References No definition available. + Details
Name: | lqda_PercentageOfReimbursementOfDocumentedOutOfPocketExpenditures
Namespace Prefix: | lqda_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate amount of reimbursement capital expenditure incurred by the supplier after the effective date of agreement to perform the services for the company. + References No definition available. + Details
Name: | lqda_ReimbursementOfCapitalExpenditureIncurredBySupplier
Namespace Prefix: | lqda_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Term of submission of quarterly forecast of expected production. + References No definition available. + Details
Name: | lqda_TermOfSubmissionOfQuarterlyForecastOfExpectedProduction
Namespace Prefix: | lqda_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_OtherCommitmentsAxis=lqda_PharmosaLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_NorthAmericaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=lqda_OtherThenNorthAmericaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_OtherCommitmentsAxis=lqda_ChasmTechnologiesAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_OtherCommitmentsAxis=lqda_AgreementWithLGMPharmaLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_OtherCommitmentsAxis=lqda_AmendedAndRestatedCommercialManufacturingServicesAndSupplyAgreementWithLonzaTampaLlcMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |